@article {Li2101399, author = {Li, Guowei and Zhang, Xuhui and Liu, Yingxin and Zhang, Junguo and Li, Likang and Huang, Xin and Thabane, Lehana and Lip, Gregory Y.H.}， title ={使用葡萄糖胺与肺癌风险的关系:来自全国前瞻性队列研究的数据}，位置-id = {2101399}， year = {2021}， doi = {10.1183/13993003.01399-2021}， publisher ={欧洲呼吸学会}，abstract ={背景研究表明，葡萄糖胺具有抗炎和抗癌的好处，但188bet官网地址副作用很小。我们的目的是基于大规模英国生物银行前瞻性队列研究的数据，探讨葡萄糖胺的使用与肺癌风险和肺癌死亡率之间的关系。方法在2006年至2010年期间招募参与者，并随访至2020年。采用Cox比例危害模型评估葡萄糖胺的使用与肺癌风险和肺癌死亡率的关系。进行亚组分析和敏感性分析，以探讨潜在的影响修改和主要发现的稳健性。结果共439393名参与者(平均年龄56岁;53\%女性)，平均随访11年。有82,603(18.80\%)参与者报告在基线时定期服用葡萄糖胺。在随访期间，记录了1971例(0.45%)肺癌事件。在完全调整的模型中，使用葡萄糖胺与肺癌风险降低(风险比=0.84,95\% CI: 0.75{textendash}0.92, p\<0.001)和肺癌死亡率降低(风险比=0.88,95\% CI: 0.81{textendash}0.96, p=0.002)显著相关。有肺癌家族史的参与者与没有肺癌家族史的参与者相比，服用葡萄糖胺与降低肺癌风险之间有更强的相关性。结论:根据这项全国性前瞻性队列研究的数据，定期服用葡萄糖胺与降低肺癌风险和肺癌死亡率显著相关。脚注本手稿最近已被接受发表在欧洲呼吸杂志。 It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. li has nothing to disclose.Conflict of interest: Dr. Zhang has nothing to disclose.Conflict of interest: Dr. Liu has nothing to disclose.Conflict of interest: Dr. Zhang has nothing to disclose.Conflict of interest: Dr. Li has nothing to disclose.Conflict of interest: Dr. Huang has nothing to disclose.Conflict of interest: Dr. Thabane has nothing to disclose.Conflict of interest: Dr. Lip reports other from Novartis, Bayer/Janssen, Biotronik, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Verseon, and Daiichi-Sankyo, other from Medtronic, Bayer, BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo, outside the submitted work; .}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/early/2021/07/21/13993003.01399-2021}, eprint = {//www.qdcxjkg.com/content/early/2021/07/21/13993003.01399-2021.full.pdf}, journal = {European Respiratory Journal} }